Aix-en-Provence, 17 June 2025 (8.00 a.m.) HIGHCO: EXCLUSIVE NEGOTIATIONS WITH SMP SAS TO ACQUIRE ITS PROMOTION (SOGEC) AND MARKETING (BUDGETBOX) ACTIVITIES HighCo announces that it has entered exclusive negotiations with SMP SAS, a subsidiary of Groupe La Poste, over the acquisition of certain businesses offering promotional marketing solutions. As part of this deal, SMP SAS would sell the promotion execution and management businesses sold under the Sogec brand, as well as its retail media subsidiary Budget ...

Back in this day in history, all the way back in 2017. That was when Amazon stunned investors with an almost $14 billion deal to buy Whole Foods. That announcement sent shockwaves across the industry.Shares of grocery chains like Kroger and SUPERVALU plunged as much as 20%. Investors really pondering what a cutthroat price competitor like Amazon would mean for an already cutthroat, low margin world of groceries. Broadline retailers like Target Slid and even real estate companies like PIMCO sold off.Now, whi ...

Core Insights - Streamline Health Solutions reported a total revenue increase of approximately 12% to $4.8 million for the first quarter of fiscal 2025 compared to $4.3 million in the same period of fiscal 2024, driven by new SaaS contracts despite some client non-renewals [2][4] - SaaS revenue grew by 23% to $3.4 million, representing 70% of total revenue in Q1 2025, up from 63% in Q1 2024 [3] - The company experienced a reduced net loss of $1.6 million in Q1 2025, an improvement from a net loss of $2.7 million in Q1 2024, attributed to increased revenue and cost savings from strategic restructuring [4][5] - Streamline Health Solutions entered into a definitive merger agreement with MDaudit for an all-cash transaction valued at approximately $37.4 million, with a share price premium of 138% over the last trading day prior to the announcement [6] Financial Performance - Total revenue for Q1 2025 was $4.8 million, a 12% increase from $4.3 million in Q1 2024 [2] - SaaS revenue for Q1 2025 was $3.4 million, a 23% increase from $2.7 million in Q1 2024, making up 70% of total revenue [3] - Adjusted EBITDA improved to $0.2 million in Q1 2025 from a loss of $0.7 million in Q1 2024, reflecting the company's focus on SaaS revenue growth and cost savings [5][18] Balance Sheet and Cash Flow - As of April 30, 2025, cash and cash equivalents were $1.4 million, down from $2.2 million as of January 31, 2025 [4][16] - Total assets increased to $35.8 million as of April 30, 2025, compared to $35.6 million as of January 31, 2025 [16] - Total liabilities rose to $24.8 million as of April 30, 2025, from $23.3 million as of January 31, 2025 [16] Merger Agreement - The merger with MDaudit is expected to close in the third quarter of calendar year 2025, with MDaudit acquiring all outstanding shares of Streamline stock for $5.34 per share [6]

Castlelake, owner of a 79% stake in AEDAS, has signed an irrevocable agreement to sell its stake to Neinor for €24.485/sh (€21.335/sh post div.) Acquisition of a premium portfolio with c.€2bn GAV (c.20,200#) at a c.30% NAV discount Conservative underwriting targeting a +20% IRR and 1.8x MOIC, implying significant de-risking and acceleration of Neinor’s Strategic Plan 2023-27: Highly accretive transaction, driving €150mn Earnings uplift over 2025-27 (+40% vs Strategic Plan target and c.+25% on EPS), and ...

Summary of Commerce Bancshares (CBSH) M&A Conference Call Company and Industry - **Company**: Commerce Bancshares Inc. - **Acquired Company**: Finemark Holdings Inc. (holding company of Finemark National Bank and Trust) - **Industry**: Banking and Wealth Management Core Points and Arguments 1. **Acquisition Announcement**: Commerce Bancshares announced the acquisition of Finemark Holdings, a private bank with nearly $8 billion in assets under management and $4 billion in banking assets, aiming to expand its presence in high-growth markets like Florida, Arizona, and South Carolina [5][6][10]. 2. **Wealth Management Focus**: The acquisition aligns with Commerce's strategy to enhance its wealth management platform, as Finemark has a strong non-interest revenue model, with 43% of its total revenue coming from non-interest sources [8][9]. 3. **Credit Quality**: Finemark has a strong credit history with only 13 basis points of cumulative net charge-offs over the last ten years, indicating a conservative approach to lending [9]. 4. **Combined Assets**: Post-acquisition, the combined entities will manage over $84 billion in total wealth assets, making it the sixteenth largest bank-managed trust company in the U.S. [10]. 5. **Leadership Transition**: Joseph Caddy, Chairman and CEO of Finemark, will become Chairman of Commerce Trust, ensuring continuity and leveraging his leadership experience [10]. 6. **Financial Metrics**: The deal is structured as a 100% stock transaction valued at approximately $585 million, with an EPS accretion of 6% expected once cost savings are realized [12][13]. 7. **Cost Savings and Integration**: Expected pre-tax cost savings of $15 million represent 15% of Finemark's non-interest expenses, with a focus on low integration risk due to similar business models [14][15]. 8. **Future Growth Potential**: The acquisition is expected to enhance Commerce's ability to drive sustainable growth, particularly in wealth management and private banking [18]. Additional Important Content 1. **Long-term Relationship**: The relationship with Finemark has been built over five years, indicating a strategic and measured approach to the acquisition [23][24]. 2. **Market Expansion**: The acquisition allows Commerce to solidify its presence in Florida and expand into Arizona and South Carolina, which are identified as attractive growth markets [8][51]. 3. **Asset Sensitivity**: The loan portfolio composition is expected to be similar to Commerce's, with asset repricing anticipated to enhance margins [25][26]. 4. **M&A Strategy**: While this is the first bank deal since 2013, Commerce maintains that M&A is part of its long-term strategy, focusing on commercial and wealth-focused banks [30][32]. 5. **Dividend and Buyback Plans**: Commerce plans to maintain its dividend policy and may resume stock buybacks in the second half of the year, despite the acquisition [54][55]. This summary encapsulates the key points from the conference call regarding the acquisition of Finemark Holdings by Commerce Bancshares, highlighting the strategic rationale, financial implications, and future growth opportunities.

Core Viewpoint - FOXO Technologies Inc. has established a new wholly-owned subsidiary, FOXO Acquisition Corporation, aimed at acquiring targets in the healthcare services sector, while also planning to create a new series of non-convertible preferred stock to facilitate these acquisitions [1][2]. Group 1: Company Developments - On June 13, 2025, FOXO formed FOXO Acquisition Corporation in Florida to pursue targeted acquisitions [2]. - The company plans to issue a new series of non-convertible preferred stock, which is expected to be publicly listed and will generate cash and common stock dividends for investors [2]. - CEO Seamus Lagan expressed optimism about the acquisition strategy, emphasizing non-dilutive funding for common stockholders and targeting acquisitions with significant growth potential [3]. Group 2: Leadership Changes - The company announced the passing of Interim Chief Financial Officer Martin Ward on June 9, 2025, and Seamus Lagan has been appointed as the Interim CFO while a search for a permanent replacement is underway [4]. Group 3: Company Overview - FOXO operates three subsidiaries: Rennova Community Health, which runs a critical access hospital in East Tennessee; Myrtle Recovery Centers, a behavioral health facility; and FOXO Labs, a biotechnology company focused on health and lifespan improvement [6][7].

Key Takeaways ALL is benefiting from rising auto renewals, strong margins and a digital transformation strategy. BRK.B's insurance arm drives growth, backed by solid pricing, underwriting, and more than $100B in cash. ALL outperforms BRK.B on return on equity, despite higher debt and geographic concentration risk.Improved pricing, rising climate-related risks and rapid digitalization are poised to shape the insurance industry's trajectory in 2025. While insurers continue to face exposure to catastrophe lo ...

Key Takeaways TMO faces margin pressure from weak macro trends, supply disruptions and rising operating expenses. Foreign exchange volatility and global expansion heighten risk to Thermo Fisher's international revenues. TMO's $4.1B Solventum deal aims to boost biologics growth and deliver $125M in synergy over five years.Thermo Fisher (TMO) suffers from macroeconomic issues. Also, competitive headwinds and currency fluctuations continue to dampen top-line growth. The stock carries a Zacks Rank #4 (Sell) c ...

Key Takeaways ALLE will acquire ELATEC for $379.1 million to strengthen its global access technology capabilities. ELATEC adds RFID expertise and supports nearly 100 credential types in global markets. The deal supports ALLE's growth via acquisitions, enhancing non-residential electronics offerings.Allegion plc (ALLE) recently inked a definitive deal to acquire ELATEC, including Elatec GmbH and other group entities (ELATEC), from Summit Partners through one of its subsidiaries. The deal is valued at €330 ...

Core Insights - Amedisys is expected to benefit from valuable partnerships and acquisitions that will generate significant synergies in the upcoming quarters, while facing challenges from a dull macroeconomic environment and competitive pressures [2][4][6] Company Performance - Amedisys shares have increased by 5.9% over the past year, outperforming the industry growth of 3.4% and the S&P 500's growth of 11% [3] - The company has a market capitalization of $3.18 billion and an earnings yield of 5.1%, which is higher than the industry's 4.2% [3] Strategic Initiatives - Amedisys is expanding its business through strategic partnerships and acquisitions, including participation in a new Medicare alternative payment model aimed at supporting dementia patients [4] - The company has introduced advanced molecular testing in collaboration with Patient Choice Laboratories to enhance diagnostic accuracy and speed [4] Clinical Quality - Amedisys has achieved an average Quality of Patient Care star rating of 4.18, with 88% of its care centers receiving 4 stars or higher, and 11 centers achieving a perfect 5-star rating [5][7] - The Patient Satisfaction star average stands at 4.02, exceeding the industry average [5] Market Challenges - The company faces macroeconomic pressures, including high labor costs due to inflation, which are expected to persist through 2025 [6] - Amedisys operates in a fragmented market with intense competition from local and hospital-owned providers, impacting its growth potential [8] Financial Estimates - The Zacks Consensus Estimate for Amedisys' 2025 earnings per share has decreased by 0.4% to $4.90, while the revenue estimate is projected at $2.46 billion, reflecting a 4.6% increase from the previous year [9]